After the BBC reported that its executive was discovered to have been involved in the sale of syrups containing codeine in the ‘black market’, Emzor Pharmaceuticals announced a suspension on the distribution of such syrups.
In a statement issued on Tuesday, the company said the distribution had been suspended pending the outcome of a “full and thorough internal investigation” on the issue.
It, however, denied that it is involved in its direct sales to members of the public.
Below is the full statement from Emzor:
Emzor Pharmaceuticals is a responsible and ethical company with over 120 lines including Emzolyn with Codeine under licence from NAFDAC. Emzor is treating the findings of the BBC documentary with the upmost seriousness and has launched a full and through investigation. Emzor adheres fully to the documentation guidelines for the handling, production, storing and distribution of products containing codeine.
Our staff are trained on the controlled status of codeine and codeine products and supply guidelines. Emzor is not involved in the direct sales to individual members of the public. Emzor does not sanction the supply of Emzolyn with Codeine in any way that breaches the Dangerous Drugs Act or NAFDAC guidelines. Emzor’s daily production is below 0.5% of the reported estimated daily amounts of codeine reportedly consumed in Kano and Jigawa States. The Sales Rep depicted in the BBC video was initially placed on suspension and has now been summarily dismissed following an investigation. Any representations made by the Sales Rep are in breach of company policy and ethics and were undertaken independently by him.
The distribution of Emzolyn with Codeine has been suspended pending the results of a full and thorough internal investigation. We hope the findings of the documentary will shed further light on the extent and impact of the illicit trade and consumption of codeine. We hope that full stakeholder engagement will result in impactful action against the abuse, smuggling and faking of drugs on the continent. Thank you.